Abstract
To compare the complication rate and effectiveness of mitomycin C (MMC), Ologen alone, and Ologen with 5-fluorouracil (5-FU) as adjunctives with Ex-PRESS mini shunt for medically uncontrolled glaucoma. Retrospective comparative study of 59 Ex-PRESS mini shunt trabeculectomy operations coupled with Ologen implantation alone, transient MMC application or Ologen implantation with 5-FU as adjunctive treatment. Eight eyes (7 patients) received Ologen alone, 37 eyes (34 patients) received MMC, and 14 eyes (14 patients) received Ologen with 5-FU as adjunctive therapy. Baseline characteristics, adjunctive used during operation, along with outcomes including intraocular pressure (IOP), number of anti-hypertensive drops, visual acuity, and complications were documented and compared. The primary outcome was IOP at 12 months. Variables were compared with r × c Fisher tests. The Ologen only group had a significantly higher IOP at 12 months (20.5 ± 10.23 mmHg) compared with Ologen combined with 5-FU (12.2 ± 1.47 mmHg) or MMC (13.8 ± 4.37 mmHg) (p = 0.015, linear mixed model). The Ologen only cohort also had a higher re-operation rate (p = 0.01, Fisher’s Exact Test) and higher rate of bleb leak (p = 0.02, Fisher’s Exact Test). Visual acuity was similar among all three groups. 5-FU with Ologen is as effective as MMC in maintaining IOP following Ex-PRESS shunt surgery at 1 year. However, Ologen alone may not be as effective as the other two adjunctive agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Maris PJ Jr, Ishida K, Netland PA (2007) Comparison of trabeculectomy with Ex-PRESS miniature glaucoma device implanted under scleral flap. J Glaucoma 16(1):14–19
Boey PY, Narayanaswamy A, Zheng C, Perera SA, Htoon HM, Tun TA et al (2011) Imaging of blebs after phacotrabeculectomy with ologen collagen matrix implants. Br J Ophthalmol 95(3):340–344
Singh K, Mehta K, Shaikh NM, Tsai JC, Moster MR, Budenz DL et al (2000) Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. Ophthalmology 107(12):2305–2309
Lin ZJ, Li Y, Cheng JW, Lu XH (2012) Intraoperative mitomycin C versus intraoperative 5-fluorouracil for trabeculectomy: a systematic review and meta-analysis. J Ocul Pharmacol Ther 28(2):166–173
DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC (2002) Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol 120(3):297–300
Chen HS, Ritch R, Krupin T, Hsu WC (2006) Control of filtering bleb structure through tissue bioengineering: an animal model. Invest Ophthalmol Vis Sci 47(12):5310–5314
Hsu WC, Spilker MH, Yannas IV, Rubin PA (2000) Inhibition of conjunctival scarring and contraction by a porous collagen–glycosaminoglycan implant. Invest Ophthalmol Vis Sci 41(9):2404–2411
Cillino S, Di Pace F, Cillino G, Casuccio A (2011) Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial. Eye (Lond) 25(12):1598–1606
Johnson MS, Sarkisian SR Jr (2013) Using a collagen matrix implant (ologen) versus mitomycin-C as a wound healing modulator in trabeculectomy with the Ex-PRESS mini glaucoma device: a 12-month retrospective review. J Glaucoma. doi: 10.1097/IJG.0000000000000018
Marey HM, Mandour SS, Ellakwa AF (2013) Subscleral trabeculectomy with mitomycin-C versus ologen for treatment of glaucoma. J Ocul Pharmacol Ther 29(3):330–334
Papaconstantinou D, Georgalas I, Karmiris E, Diagourtas A, Koutsandrea C, Ladas I et al (2010) Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study. Acta Ophthalmol 88(1):80–85
Narayanaswamy A, Perera SA, Htoon HM, Hoh ST, Seah SK, Wong TT et al (2013) Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year. Clin Experiment Ophthalmol 41(6):552–560
Rosentreter A, Gaki S, Cursiefen C, Dietlein TS (2014) Trabeculectomy using mitomycin C versus an atelocollagen implant: clinical results of a randomized trial and histopathologic findings. Ophthalmologica 231(3):133–140
Rosentreter A, Schild AM, Jordan JF, Krieglstein GK, Dietlein TS (2010) A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma. Eye (Lond) 24(9):1449–1457
He M, Wang W, Zhang X, Huang W (2014) Ologen implant versus mitomycin C for trabeculectomy: a systematic review and meta-analysis. PLoS One 9(1):e85782
Salim S (2012) Current variations of glaucoma filtration surgery. Curr Opin Ophthalmol 23(2):89–95
Song A, Scott IU, Flynn HW Jr, Budenz DL (2002) Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology 109(5):985–991
Conflict of interest
The authors declare that they have no conflict of interest and did not receive funding from any party for this research.
Author information
Authors and Affiliations
Corresponding author
Additional information
Shivali A. Menda and Eugene A. Lowry have contributed equally to this work and are co-first authors.
Rights and permissions
About this article
Cite this article
Menda, S.A., Lowry, E.A., Porco, T.C. et al. Ex-PRESS outcomes using mitomycin-C, Ologen alone, Ologen with 5-fluorouracil. Int Ophthalmol 35, 357–363 (2015). https://doi.org/10.1007/s10792-014-9955-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-014-9955-3